Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jamie Kim

Clinical Cardiac Electrophysiology Londonderry, NH Medical Doctor

NPI 1235178187 CMS profile 11126

6 Buttrick Rd Ste 200, Londonderry, NH 03053

Open in the dashboard

General payments

$386,322

448 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,020,263 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jamie Kim of Londonderry, NH is reported in the CMS Open Payments database as having received $386,322 across 448 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,020,263 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $80,232 79
2024 General $50,087 88
2023 General $45,792 59
2022 General $39,094 44
2021 General $24,769 33
2020 General $56,289 41
2019 General $90,058 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamie Kim
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Jamie Kim were reported at $80,232. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Jamie Kim Clinical Cardiac Electrophysiology median Middle half National median
2019 $90,058 $2,361 $585–$8,260 $163
2020 $56,289 $993 $247–$4,351 $114
2021 $24,769 $1,185 $326–$4,739 $132
2022 $39,094 $2,073 $554–$6,789 $149
2023 $45,792 $2,568 $759–$8,159 $160
2024 $50,087 $2,557 $703–$7,403 $164
2025 $80,232 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $326,335 302 payments
  2. Janssen Pharmaceuticals, Inc $34,354 37 payments
  3. Biosense Webster, Inc. $19,245 26 payments
  4. Abbott Laboratories $3,905 51 payments
  5. Medical Device Business Services, Inc. $769 4 payments
  6. Biotronik Inc. $401 4 payments
  7. Atricure, Inc. $263 2 payments
  8. Medtronic Vascular, Inc. $211 2 payments
  9. Inari Medical, Inc. $189 2 payments
  10. Edwards Lifesciences Corporation $143 2 payments
  11. Other $506 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $227,015 80 payments
  2. Consulting Fee $99,875 36 payments
  3. Travel and Lodging $44,307 161 payments
  4. Food and Beverage $15,115 169 payments
  5. Education $10 2 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Access System Watchman_Ic $64,004 74 payments
  2. WATCHMAN Structural Heart $55,143 47 payments
  3. XARELTO $34,354 37 payments
  4. General - Therapies $23,321 8 payments
  5. RHYTHMIA $19,078 10 payments
  6. WATCHMAN WATCHMAN Pro_IC $18,750 4 payments
  7. FARAPULSE $17,444 8 payments
  8. Carto 3 $17,161 12 payments
  9. WATCHMAN FLX $14,445 11 payments
  10. WATCHMAN Access System Structural Heart $13,230 5 payments
  11. Other $65,630 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,651

Median for Cardiology: 2,533

Drug cost

$477,595

Median for Cardiology: $485,213

Branded share of claims

46.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 362 $351,785
Xarelto Rivaroxaban Brand 104 $104,755
Metoprolol Succinate Generic 307 $4,560
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 24 $4,062
Flecainide Acetate Generic 59 $3,656
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 72 $1,788
Clopidogrel Clopidogrel Bisulfate Brand 126 $908
Sotalol Sotalol Hcl Brand 47 $899
Potassium Chloride Generic 39 $721
Amiodarone Hcl Generic 70 $661

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$319,943

Of which drugs: $108

Medicare patients

2,086

Average age 76

Services billed

4,745

973 women, 1,113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 60%
Ischemic heart disease 52%
Arthritis 49%
Heart failure 48%
Chronic kidney disease 34%
Diabetes 32%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 12 48 $108

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $28
$28 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $23
$23 — —
VYNDAQEL
  • PFIZER INC. $19
$19 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $9
$9 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

448 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record